Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

Research output: Contribution to journalArticle

Abstract

Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.

Original languageEnglish
Pages (from-to)162-177
Number of pages16
JournalJNCI Monographs
Volume41
DOIs
Publication statusPublished - 1 Jan 2010

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast
Radiotherapy
Segmental Mastectomy
Adjuvant Radiotherapy
Tamoxifen
Neoplasms

Keywords

  • breast cancer
  • oncology
  • clinical trials
  • radiotherapy

Cite this

@article{e90245ab8efe4c0eb8cd8167e6c9bd34,
title = "Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast",
abstract = "Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2{\%} (SE 1.6{\%}, 12.9{\%} vs 28.1{\%} 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.",
keywords = "breast cancer, oncology, clinical trials, radiotherapy",
author = "Jon Godwin",
note = "<p>Originally published in: JNCI Monographs (2010), 41, pp.162-177.</p>",
year = "2010",
month = "1",
day = "1",
doi = "10.1093/jncimonographs/lgq039",
language = "English",
volume = "41",
pages = "162--177",
journal = "JNCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press (OUP)",

}

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. / Godwin, Jon.

In: JNCI Monographs, Vol. 41, 01.01.2010, p. 162-177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

AU - Godwin, Jon

N1 - <p>Originally published in: JNCI Monographs (2010), 41, pp.162-177.</p>

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.

AB - Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.

KW - breast cancer

KW - oncology

KW - clinical trials

KW - radiotherapy

U2 - 10.1093/jncimonographs/lgq039

DO - 10.1093/jncimonographs/lgq039

M3 - Article

VL - 41

SP - 162

EP - 177

JO - JNCI Monographs

JF - JNCI Monographs

SN - 1052-6773

ER -